Earth Science Tech, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Earth Science Tech, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Mar 31, 2015 | $80.3K | May 10, 2016 |
| FY2014 | Mar 31, 2014 | $7.5K | May 10, 2016 |
| FY2013 | Mar 31, 2013 | $41.9K | Jul 16, 2014 |
| FY2012 | Mar 31, 2012 | $22.4K | May 10, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $33.12M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $11.95M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $48.5K | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $14.1K | Feb 27, 2024 |
| FY2022 | Mar 31, 2021 | $140.9K | Jul 22, 2022 |
| FY2021 | Mar 31, 2020 | $526.1K | Feb 22, 2022 |
| FY2020 | Mar 31, 2019 | $770.6K | Aug 10, 2020 |
| FY2019 | Mar 31, 2018 | $463.1K | Jul 8, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $24.30M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $7.83M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $22.1K | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | ($8.5K) | Feb 27, 2024 |
| FY2022 | Mar 31, 2021 | $39.9K | Jul 22, 2022 |
| FY2021 | Mar 31, 2020 | $218.5K | Feb 22, 2022 |
| FY2020 | Mar 31, 2019 | $295.0K | Aug 10, 2020 |
| FY2019 | Mar 31, 2018 | $192.9K | Jul 8, 2019 |
| FY2014 | Mar 31, 2015 | $3.2K | May 10, 2016 |
| FY2014 | Mar 31, 2014 | $6.6K | May 10, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $3.25M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $812.1K | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | ($365.4K) | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $3.17M | Feb 27, 2024 |
| FY2022 | Mar 31, 2021 | ($4.38M) | Jul 22, 2022 |
| FY2021 | Mar 31, 2020 | ($1.20M) | Feb 22, 2022 |
| FY2020 | Mar 31, 2019 | ($2.22M) | Aug 10, 2020 |
| FY2019 | Mar 31, 2018 | ($1.71M) | Jul 8, 2019 |
| FY2014 | Mar 31, 2015 | ($8.77M) | May 10, 2016 |
| FY2014 | Mar 31, 2014 | ($12.54M) | May 10, 2016 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Mar 31, 2024 | $892.3K | Jun 28, 2024 |
| FY2024 | Mar 31, 2023 | ($936.7K) | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | ($226.7K) | Feb 27, 2024 |
| FY2022 | Mar 31, 2021 | ($4.30M) | Jul 22, 2022 |
| FY2021 | Mar 31, 2020 | ($908.6K) | Feb 22, 2022 |
| FY2020 | Mar 31, 2019 | ($2.14M) | Aug 10, 2020 |
| FY2019 | Mar 31, 2018 | ($1.71M) | Jul 8, 2019 |
| FY2014 | Mar 31, 2015 | ($8.77M) | May 10, 2016 |
| FY2014 | Mar 31, 2014 | ($12.54M) | May 10, 2016 |
| FY2013 | Mar 31, 2013 | ($61.5K) | Jul 16, 2014 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $0 | Feb 27, 2024 |
| FY2023 | Mar 31, 2022 | $0 | Feb 27, 2024 |
| FY2022 | Mar 31, 2021 | $9.0K | Jul 22, 2022 |
| FY2021 | Mar 31, 2020 | $76.1K | Feb 22, 2022 |
| FY2020 | Mar 31, 2019 | $338.9K | Aug 10, 2020 |
| FY2019 | Mar 31, 2018 | $150.5K | Jul 8, 2019 |
| FY2014 | Mar 31, 2015 | $32.6K | May 10, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $4.15M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $167.0K | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $231.9K | Jun 28, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $4.37M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $1.21M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | ($1.01M) | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | ($168.1K) | Feb 27, 2024 |
| FY2022 | Mar 31, 2021 | ($196.7K) | Jul 22, 2022 |
| FY2021 | Mar 31, 2020 | ($518.6K) | Feb 22, 2022 |
| FY2020 | Mar 31, 2019 | ($1.64M) | Aug 10, 2020 |
| FY2019 | Mar 31, 2018 | ($1.07M) | Jul 8, 2019 |
| FY2014 | Mar 31, 2015 | ($376.4K) | May 10, 2016 |
| FY2014 | Mar 31, 2014 | ($241.9K) | May 10, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Mar 31, 2024 | $26.5K | Jun 28, 2024 |
| FY2014 | Mar 31, 2015 | $69.0K | May 10, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $7.07M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $3.88M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $2.73M | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $76.9K | Feb 27, 2024 |
| FY2022 | Mar 31, 2021 | $64.6K | Jul 22, 2022 |
| FY2021 | Mar 31, 2020 | $154.6K | Feb 22, 2022 |
| FY2020 | Mar 31, 2019 | $411.1K | Aug 10, 2020 |
| FY2019 | Mar 31, 2018 | $345.3K | Jul 8, 2019 |
| FY2014 | Mar 31, 2015 | $773.7K | May 10, 2016 |
| FY2014 | Mar 31, 2014 | $905.0K | May 10, 2016 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $3.22M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $1.63M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $1.61M | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $1.88M | Feb 27, 2024 |
| FY2022 | Mar 31, 2021 | $5.09M | Jul 22, 2022 |
| FY2021 | Mar 31, 2020 | $980.4K | Feb 22, 2022 |
| FY2020 | Mar 31, 2019 | $617.7K | Aug 10, 2020 |
| FY2019 | Mar 31, 2018 | $465.3K | Jul 8, 2019 |
| FY2014 | Mar 31, 2015 | $148.2K | May 10, 2016 |
| FY2014 | Mar 31, 2014 | $205.9K | May 10, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $3.85M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $2.25M | Jun 27, 2025 |
| FY2025 | Mar 31, 2023 | $1.12M | Jun 27, 2025 |
| FY2024 | Mar 31, 2022 | ($1.81M) | Jun 28, 2024 |
| FY2023 | Mar 31, 2021 | ($5.03M) | Feb 27, 2024 |
| FY2022 | Mar 31, 2020 | ($825.8K) | Jul 22, 2022 |
| FY2021 | Mar 31, 2019 | ($206.7K) | Feb 22, 2022 |
| FY2020 | Mar 31, 2018 | ($120.0K) | Aug 10, 2020 |
| FY2019 | Mar 31, 2017 | $9.3K | Jul 8, 2019 |
| FY2014 | Mar 31, 2015 | $625.5K | May 10, 2016 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.30M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | $2.30M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | $2.30M | Jun 28, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($27.74M) | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | ($29.66M) | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | ($30.47M) | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | ($30.12M) | Feb 27, 2024 |
| FY2022 | Mar 31, 2021 | ($33.30M) | Jul 22, 2022 |
| FY2021 | Mar 31, 2020 | ($28.91M) | Feb 22, 2022 |
| FY2020 | Mar 31, 2019 | ($27.71M) | Aug 10, 2020 |
| FY2019 | Dec 31, 2018 | $27.15M | Jul 1, 2019 |
| FY2019 | Mar 31, 2018 | ($25.50M) | Jul 8, 2019 |
| FY2014 | Mar 31, 2015 | ($21.42M) | May 10, 2016 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $607.6K | Jun 27, 2025 |
| FY2023 | Mar 31, 2023 | $35.8K | Feb 27, 2024 |
| FY2023 | Mar 31, 2022 | $26.9K | Feb 27, 2024 |
| FY2022 | Mar 31, 2021 | $16.2K | Jul 22, 2022 |
| FY2021 | Mar 31, 2020 | $30.7K | Feb 22, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Mar 31, 2023 | $809.2K | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | $780.7K | Feb 27, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Feb 27, 2024 |
| FY2022 | Mar 31, 2021 | 0 | Jul 22, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | 0 | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Jun 28, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 294.30M | Jun 27, 2025 |
| FY2025 | Mar 31, 2024 | 309.98M | Jun 27, 2025 |
| FY2024 | Mar 31, 2023 | 282.61M | Jun 28, 2024 |
| FY2023 | Mar 31, 2022 | 53.85M | Feb 27, 2024 |
| FY2022 | Mar 31, 2021 | 50.55M | Jul 22, 2022 |
| FY2021 | Mar 31, 2020 | 37.81M | Feb 22, 2022 |
| FY2020 | Mar 31, 2019 | 52.21M | Aug 10, 2020 |
| FY2019 | Mar 31, 2018 | 46.15M | Jul 8, 2019 |
| FY2014 | Mar 31, 2015 | 38.23M | May 10, 2016 |
| FY2014 | Mar 31, 2014 | 36.73M | May 10, 2016 |